ALK and laryngotracheoesophageal cleft: The OS of patients with ALK-rearranged Sq-LC was almost 6 months shorter than that of patients with ALK-rearranged Ad-LC (14.5 ± 14.2 [2–35] vs. 20.6 ± 12.0 [1–44] months, respectively; p = 0.298), suggesting that outcomes are worse for the former as compared to the latter patient group even when ALK inhibitors are used (Figure 4C).